Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome

PURPOSE: The efficacy of levoketoconazole in treating hypercortisolism was demonstrated in an open-label phase 3 study (SONICS) of adults with endogenous Cushing’s syndrome (CS) and baseline mean urinary free cortisol (mUFC) ≥  1.5× ULN. Clinical signs and symptoms and patient-reported outcomes from...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pituitary
Main Authors: Geer, Eliza B., Salvatori, Roberto, Elenkova, Atanaska, Fleseriu, Maria, Pivonello, Rosario, Witek, Przemyslaw, Feelders, Richard A., Bex, Marie, Borresen, Stina W., Puglisi, Soraya, Biller, Beverly M. K., Cohen, Fredric, Pecori Giraldi, Francesca
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7864823/
https://ncbi.nlm.nih.gov/pubmed/33216275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11102-020-01103-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados